Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
April 29, 2024 07:59 ET
|
Pasithea
Pasithea Therapeutics' PAS-004 abstract accepted for ASCO poster presentation: novel MEK inhibitor shows promise for NF1 and cancer therapy.
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
April 24, 2024 07:59 ET
|
Pasithea
Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.
Global Thyroid Cancer Drugs Market Report 2024: Highlights Trends in Targeted Therapies, Featuring Profiles of Mylan Pharmaceuticals, AstraZeneca, Exelixis, Pfizer, and Bristol-Myers Squibb
January 23, 2024 15:28 ET
|
Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Thyroid Cancer Drugs Global Market 2024" report has been added to ResearchAndMarkets.com's offering. The global thyroid cancer drugs market...
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
January 08, 2024 07:59 ET
|
Pasithea
Pasithea Therapeutics unveils crystalline PAS-004, extending IP protection to 2045 for CNS disorder treatments.
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
January 02, 2024 08:35 ET
|
Pasithea
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3.
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
December 28, 2023 17:00 ET
|
Pasithea
Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19.
Global Thyroid Cancer Drugs Market to Reach $1.29 Billion by 2027: Targeted Therapies Transforming Thyroid Cancer Treatment
July 31, 2023 05:33 ET
|
Research and Markets
Dublin, July 31, 2023 (GLOBE NEWSWIRE) -- The "Thyroid Cancer Drugs Global Market Report 2023" has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive guide to...
Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference
June 01, 2023 07:57 ET
|
Pasithea
PALO ALTO, Calif. and MIAMI, June 01, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research,...
Global MEK Inhibitors Market, Drug Sales & Clinical Trials to 2026: USD 3 Billion Market Opportunity
November 19, 2021 05:03 ET
|
Research and Markets
Dublin, Nov. 19, 2021 (GLOBE NEWSWIRE) -- The "Global MEK Inhibitors Market, Drug Sales & Clinical Trials insight 2026" report has been added to ResearchAndMarkets.com's offering. The advances...